Open AccessRegulatory aspects on repurposing of drugs in the management of COVID-19
Author(s) -
Priyansha Bhatia,
Akash Chauhan,
Gagan Porwal,
Vikesh Kumar Shukla
Publication year - 2022
Publication title -
international journal of drug regulatory affairs
Language(s) - English
Resource type - Journals
eISSN - 2321-7162
pISSN - 2321-6794
DOI - 10.22270/ijdra.v10i1.503
Subject(s) - repurposing , tocilizumab , drug repositioning , medicine , identification (biology) , timeline , covid-19 , pharmacology , drug , engineering , infectious disease (medical specialty) , immunology , disease , biology , rheumatoid arthritis , pathology , waste management , history , botany , archaeology
Drug repurposing involves the disquisition of using medicines for new remedial purposes. With the increasing waste production, given the costs and tiresome pace of new medicine search, repurposing of medicines already in the market to treat all kinds of conditions is decreasingly getting a selective approval because uses the composites that have been de-risked, with lesser development costs and shorter timelines of developing the drug. Colourful and experimental data approaches have been used for the identification of the medicines to be repurposed. There are also major technical and non-supervisory challenges that need to be addressed. In this review, we present the different kinds of approaches used for medicine repurposing, study the challenges faced by the scientists during repurposing as well as recommend ways by which these challenges could be overcome to help realize the full potential of medicine repurposing. Drug displacing is the repurposing of an already existing medicine for the treatment of a different complaint or medical condition than that for which it was firstly developed. This is one line of scientific exploration which is being pursued to develop safe and effective COVID-19 treatments. Other exploration directions include the discovery of a COVID-19 vaccine and convalescent tube transfusion. Several being antiviral specifics, preliminarily developed or used as treatments for SARS, MERS, HIV/ AIDS, and malaria, have been delved as implicit COVID‐19 treatments, with some moving into clinical trials. Monoclonal antibodies under disquisition for repurposing include anti-IL-6 agents (tocilizumab) and anti-IL-8 (BMS-986253). This is in resemblance to new monoclonal antibody medicines developed specifically for COVID-19.